A pharmacoeconomic study of post-exposure prophylaxis strategies for influenza virus infections in Japan

Background Vaccines can prevent influenza (flu) infections and are cost-effective for society and healthcare. However, the cost-effectiveness of post-exposure prophylaxis as a follow-up strategy is unclear. This study evaluates the cost–utility of post-exposure prophylaxis and treatment strategies with neuraminidase inhibitors (NIs) and a cap-dependent endonuclease inhibitor (EI) for flu infections from the perspective of healthcare costs in Japan. 
Research design and methods A base-case analysis was used to compare oseltamivir, zanamivir, and laninamivir for Nls and baloxavir marboxil for EI. The costs of the first visit to a physician and pharmacy were excluded because of out-of-pocket for post-exposure prophylaxis in Japan. Direct medical costs included the second physician visit, pharmacy and hospital admission expenses, and drug prices, based on the 2020 Japanese Medical Fee Index. EQ-5D-5L questionnaires were utilized to measure healthy participants’ quality of life scores, with ..., , , # A pharmacoeconomic study of post-exposure prophylaxis strategies for influenza virus infections in Japan

[https://doi.org/10.5061/dryad.tqjq2bw47](https://doi.org/10.5061/dryad.tqjq2bw47)

## Author(s)

Naoto Nakagawa, Phar.D., Ph.D.
School of Pharmaceutical Sciences, Ohu University, Koriyama, Fukushima, Japan
31-1 Misumido, Tomita-machi, Koriyama, Fukushima 963-8611, Japan
Email: [[e-mail]](mailto:[e-mail])

Runa Ono
31-1 Misumido, Tomita-cho, Koriyama, Fukushima, 963-8611, Japan
Phone: [phone], Email: [[e-mail]](mailto:[e-mail])

Odanaka, Ph.D.
31-1 Misumido, Tomita-cho, Koriyama, Fukushima, 963-8611, Japan
Phone: [phone], Email: [[e-mail]](mailto:[e-mail])

Hiroshi Ohara, Ph.D.
31-1 Misumido, Tomita-cho, Koriyama, Fukushima, 963-8611, Japan
Phone: [phone], Email: [[e-mail]](mailto:[e-mail])

Shigeki Kisara, Ph.D.
31-1 Misumido, Tomita-cho, Koriy...

研究背景
疫苗可预防流感（influenza，flu）感染，且对社会与医疗卫生系统具备成本效益。然而，作为后续干预策略的暴露后预防（post-exposure prophylaxis）方案，其成本效益仍尚不明确。本研究从日本医疗费用视角出发，评估了采用神经氨酸酶抑制剂（neuraminidase inhibitors, NIs）与帽依赖性核酸内切酶抑制剂（cap-dependent endonuclease inhibitor, EI）的流感暴露后预防与治疗策略的成本效用。

研究设计与方法
本研究采用基础情景分析，对比了神经氨酸酶抑制剂类的奥司他韦、扎那米韦与拉尼米韦，以及帽依赖性核酸内切酶抑制剂类的玛巴洛沙韦。由于日本的暴露后预防费用由患者自费，因此首次门诊与购药成本被排除在统计范围外。直接医疗成本则基于2020年日本医疗费用指数进行核算，涵盖二次门诊、购药、住院支出以及药品价格。本研究采用EQ-5D-5L量表对健康受试者的生命质量评分进行测量，详见……

# 日本流感病毒感染暴露后预防策略的药物经济学研究
[https://doi.org/10.5061/dryad.tqjq2bw47](https://doi.org/10.5061/dryad.tqjq2bw47)

作者
中川直人，药学博士、哲学博士
日本福岛县郡山市奥羽大学药学院，日本福岛县郡山市富田町三水堂31-1，邮编963-8611
邮箱：[e-mail]

小野瑠奈
日本福岛县郡山市富田町三水堂31-1，邮编963-8611
电话：[phone]，邮箱：[e-mail]

小田中，哲学博士
日本福岛县郡山市富田町三水堂31-1，邮编963-8611
电话：[phone]，邮箱：[e-mail]

原田博，哲学博士
日本福岛县郡山市富田町三水堂31-1，邮编963-8611
电话：[phone]，邮箱：[e-mail]

木下茂树，哲学博士
日本福岛县郡山市富田町三水堂31-1……